Potential agreement follows positive clinical and stability data, supporting rollout in UK, Canada, Australia and New Zealand London, UK – June 15, 2026 Stablepharma Limited, specialists in thermostable formulations, today announced the signing of a Letter of Intent (LOI) with AFT Pharmaceuticals (NZX: AFT; ASX: AFP) regarding the proposed distribution of SPVX02, their lead fridge-free […]
Read More
Stablepharma’s Fridge-Free Vaccine that Eliminates the Need for Cold Chain entering First-in-Human UK Clinical Trial. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has granted approval for Stablepharma to begin a Phase I clinical trial with SPVX02, an adult booster vaccine aimed at preventing tetanus and diphtheria (Td) infections. This approval marks a major […]
Read More
Stablepharma Ltd, the Fridge-free Vaccine Company and BB-NCIPD Ltd (Bul Bio) European vaccine manufacturer, have signed a second agreement for the exclusive bulk supply and commercialisation of the Tetanus vaccine (SPVX06). This agreement follows a similar arrangement with Bul Bio for the Tetanus diphtheria vaccine (SPVX02) in September 2022. “As a result of this strategic […]
Read More